AN OPEN-LABEL STUDY TO DETERMINE THE SAFETY AND PHARMACOKINETICS OF AT1001 IN SUBJECTS WITH IMPAIRED RENAL FUNCTION AND HEALTHY SUBJECTS WITH NORMAL RENAL FUNCTION

被引：0
|
作者：
Johnson, F. K. [1 ]
Mudd, P. N., Jr. [2 ]
Sitaraman, S. [1 ]
Boudes, P. [1 ]
机构：
[1] Amicus Therapeut, Cranbury, NJ USA
[2] GlaxoSmithKline, Res Triangle Pk, NC USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2013年 / 93卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：S85 / S85
页数：1
相关论文
共 50 条
  • [1] An Open-Label Study to Determine the Pharmacokinetics and Safety of Migalastat HCl in Subjects With Impaired Renal Function and Healthy Subjects With Normal Renal Function
    Johnson, Franklin K.
    Mudd, Paul N., Jr.
    DiMino, Tara
    Vosk, Jennie
    Sitaraman, Sheela
    Boudes, Pol
    France, Nicholas
    Barlow, Carrolee
    [J]. CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2015, 4 (04): : 256 - 261
  • [2] A Phase 1, Open-Label Evaluation of the Pharmacokinetics And Safety of a Single Dose of Apraglutide in Subjects With Normal and Impaired Renal Function
    Greig, Gerard
    Cong, Danni
    Hurley, Niamh
    Michel, Eric
    Youssef, Nader
    [J]. TRANSPLANTATION, 2022, 106 (09) : S544 - S544
  • [3] A phase I open-label trial to determine the pharmacolkinetics of glucarpidase in subjects with normal and impaired renal function.
    Phillips, MA
    Auton, TR
    Ward, SB
    Smith, WB
    Balan, G
    [J]. BLOOD, 2005, 106 (11) : 191B - 191B
  • [4] Pharmacokinetics and safety of tamsulosin in subjects with normal and impaired renal or hepatic function
    Miyazawa, Y
    Blum, RA
    Schentag, JJ
    Kamimura, H
    Matsushima, H
    Swarz, H
    Ito, Y
    [J]. CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 2001, 62 (09): : 603 - 621
  • [5] The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function
    Aweeka, F
    Jayesekara, D
    Horton, M
    Swan, S
    Lambrecht, L
    Wilner, KD
    Sherwood, J
    Anziano, RJ
    Smolarek, TA
    Turncliff, RZ
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 49 : 27S - 33S
  • [6] Pharmacokinetics of glucarpidase in subjects with normal and impaired renal function
    Phillips, Marc
    Smith, William
    Balan, Guhan
    Ward, Suzanne
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 48 (03): : 279 - 284
  • [7] Asunaprevir Pharmacokinetics and Safety in Subjects With Impaired Renal Function
    Garimella, Tushar
    He, Bing
    Luo, Wen-Lin
    Colston, Elizabeth
    Zhu, Kurt
    Kandoussi, Hamza
    Marbury, Thomas C.
    Alcorn, Harry W.
    Smith, William B.
    Eley, Timothy
    [J]. HEPATOLOGY, 2013, 58 : 430A - 430A
  • [8] Pharmacokinetics and Safety of Omadacycline in Subjects with Impaired Renal Function
    Berg, Jolene K.
    Tzanis, Evan
    Garrity-Ryan, Lynne
    Bai, Stephen
    Chitra, Surya
    Manley, Amy
    Villano, Stephen
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (02)
  • [9] An open-label study of the pharmacokinetics, safety and tolerability of zibotentan (ZD4054) in subjects with mild, moderate, or severe renal impairment, or normal renal function
    Tomkinson, H. K.
    Weil, A.
    Engelhardt, E.
    Schmid, K.
    Oliver, S.
    Morris, T.
    Swaisland, H.
    Taboada, M.
    [J]. EJC SUPPLEMENTS, 2009, 7 (02): : 132 - 132
  • [10] PHARMACOKINETICS OF CEFOTAXIME IN SUBJECTS WITH NORMAL AND IMPAIRED RENAL-FUNCTION
    FILLASTRE, JP
    LEROY, A
    HUMBERT, G
    GODIN, M
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1980, 6 : 103 - 111
12345